Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
2022-11-03 • Google News
Codiak BioSciences Inc (CDAK)
US$ 00%
Price Chart
Key Statistics
Market Cap
$ 2.83M
P/E Ratio
0.00
Revenue (TTM)
$ 34.07M
Volume
0
52W High
$ 0.00
52W Low
$ 0.00
Dividend Yield
0.00%
Beta
3.94
Technicals
50-Day MA
0.4073
200-Day MA
1.0006
52 Week High
N/A
52 Week Low
N/A
About CDAK
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases,.
Employees
102
Headquarters
Cambridge, MA
CEO
Dr. Douglas Edward Williams Ph.D.